NASDAQ:TCRRTcr2 Therapeutics Stock Price, Forecast & News

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TCRR shares have increased by 17.7% and is now trading at $10.10. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tcr2 Therapeutics.

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tcr2 Therapeutics.

Tcr2 Therapeutics Inc (NASDAQ:TCRR) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.05. View Tcr2 Therapeutics' earnings history.

4 Wall Street analysts have issued twelve-month price objectives for Tcr2 Therapeutics' shares. Their forecasts range from $16.00 to $19.00. On average, they anticipate Tcr2 Therapeutics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 73.3% from the stock's current price. View analysts' price targets for Tcr2 Therapeutics.

News coverage about TCRR stock has trended very negative on Saturday, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tcr2 Therapeutics earned a news sentiment score of -3.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutTcr2 Therapeutics.

Tcr2 Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 794,800 shares, a decrease of 7.3% from the April 30th total of 857,200 shares. Based on an average daily trading volume, of 84,200 shares, the days-to-cover ratio is presently 9.4 days. Currently, 6.5% of the company's shares are sold short. View Tcr2 Therapeutics' Current Options Chain.

Some companies that are related to Tcr2 Therapeutics include BAVARIAN NORDIC/S (BVNRY), Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Compugen (CGEN), Cellectis (CLLS), BioCryst Pharmaceuticals (BCRX), Avrobio (AVRO), Replimune Group (REPL), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Nantkwest (NK) and Vericel (VCEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Harpoon Therapeutics (HARP), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), Stoke Therapeutics (STOK) and Akero Therapeutics (AKRO).

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Tcr2 Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.34%), ArrowMark Colorado Holdings LLC (5.66%), BlackRock Inc. (3.71%), JPMorgan Chase & Co. (0.94%), Geode Capital Management LLC (0.80%) and Victory Capital Management Inc. (0.35%). Company insiders that own Tcr2 Therapeutics stock include Morana Jovan-Embiricos, Neil W Gibson and Upnorth Investment Ltd. View institutional ownership trends for Tcr2 Therapeutics.

TCRR stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Morgan Stanley, UBS Group AG, First Trust Advisors LP, Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold Tcr2 Therapeutics company stock in the last year include Morana Jovan-Embiricos, and Neil W Gibson. View insider buying and selling activity for Tcr2 Therapeutics.

TCRR stock was bought by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, DAFNA Capital Management LLC, Soleus Capital Management L.P., IndexIQ Advisors LLC, JPMorgan Chase & Co., Geode Capital Management LLC, Parametric Portfolio Associates LLC, and BlackRock Inc.. Company insiders that have bought Tcr2 Therapeutics stock in the last two years include Morana Jovan-Embiricos, and Upnorth Investment Ltd. View insider buying and selling activity for Tcr2 Therapeutics.

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCRR stock can currently be purchased for approximately $10.10.

Tcr2 Therapeutics has a market capitalization of $243.21 million. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.

The official website for Tcr2 Therapeutics is www.tcr2.com.

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]